NeuroVasx completes $8.5M financing

TriMed Staff | | Health Imaging | Screening
NeuroVasx, a catheter and implant technologies company to treat acute stroke, aneurysms and other cerebrovascular disorders, has completed a private placement of common stock in the amount of $8.5 million with Miller Johnson Steichen Kinnard of Minneapolis, Minn., and the Stephens Group of Little Rock, Ark.

Specific terms of the financing were not disclosed.

The Maple Grove, Minn.-based company also announced completion of follow-up on 20 patients treated with the cPAX Aneurysm Treatment System in a clinical study which was completed in May. The company is scheduled to announce the study results at the 2008 International Stroke Conference held in New Orleans, La. in February.

TriMed Staff

Related Content

Rising rates of interval breast cancers have experts calling for more risk-based screenings
Rates of breast cancer diagnosis, death expected to climb in coming decades
AI quantifies breast arterial calcifications on mammograms
AI 'not safe' to be implemented as a solo reader for breast cancer screening exams
American College of Radiology announces significant expansion of Lung Cancer Screening Registry
AI beats standard regression models at predicting lung cancer risk

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.